512 related articles for article (PubMed ID: 33842331)
1. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.
Apollonio B; Ioannou N; Papazoglou D; Ramsay AG
Front Oncol; 2021; 11():626818. PubMed ID: 33842331
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy.
Nicholas NS; Apollonio B; Ramsay AG
Biochim Biophys Acta; 2016 Mar; 1863(3):471-482. PubMed ID: 26554850
[TBL] [Abstract][Full Text] [Related]
3. Immuno-oncology for B-cell lymphomas.
Choi YS
Blood Res; 2021 Apr; 56(S1):S70-S74. PubMed ID: 33935038
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application.
Mulder TA; Wahlin BE; Österborg A; Palma M
Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261914
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions.
Montironi C; Muñoz-Pinedo C; Eldering E
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33466674
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
7. The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors.
Menter T; Tzankov A; Dirnhofer S
Hematol Oncol; 2021 Feb; 39(1):3-10. PubMed ID: 33105031
[TBL] [Abstract][Full Text] [Related]
8. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma.
van Bruggen JAC; Martens AWJ; Tonino SH; Kater AP
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33353234
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade for hematologic malignancies: a review.
Pianko MJ; Liu Y; Bagchi S; Lesokhin AM
Stem Cell Investig; 2017; 4():32. PubMed ID: 28529947
[TBL] [Abstract][Full Text] [Related]
11. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
12. Immune suppression and reversal of the suppressive tumor microenvironment.
Shimizu K; Iyoda T; Okada M; Yamasaki S; Fujii SI
Int Immunol; 2018 Sep; 30(10):445-454. PubMed ID: 29939325
[TBL] [Abstract][Full Text] [Related]
13. T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209724
[TBL] [Abstract][Full Text] [Related]
14. Next-generation immunotherapies for lymphoma: one foot in the future.
Manson G; Houot R
Ann Oncol; 2018 Mar; 29(3):588-601. PubMed ID: 29365060
[TBL] [Abstract][Full Text] [Related]
15. Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8
Greenbaum AM; Fromm JR; Gopal AK; Houghton AM
Blood Res; 2022 Jun; 57(2):117-128. PubMed ID: 35551108
[TBL] [Abstract][Full Text] [Related]
16. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
18. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
19. TGFβ signaling activation correlates with immune-inflamed tumor microenvironment across human cancers and predicts response to immunotherapy.
Xia J; Zhang Q; Luan J; Min P; Zhang H; Chen G; Ji C; Song N
Cell Cycle; 2023 Jan; 22(1):57-72. PubMed ID: 35923142
[TBL] [Abstract][Full Text] [Related]
20. Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.
Kapp K; Volz B; Oswald D; Wittig B; Baumann M; Schmidt M
Oncoimmunology; 2019; 8(12):e1659096. PubMed ID: 31741757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
